ETF PROAI

PPHvsSPMD

VanEck Pharmaceutical ETF against SPDR Portfolio S&P 400 Mid Cap ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
PPH 116SPMD 112Oct 25Oct 26GROWTH OF $100
Head to head
PPHSPMD
Expense ratio0.36%0.030%
Assets$1B$17.9B
Net flow, 1 month+$44M+$207M
Net flow, 1 year+$325M+$2.1B
Return, YTD+4.7%+11.0%
Return, 1 year+15.8%+11.9%
Avg daily volume286K1.6M
Holdings27401
ListedFeb 1, 2000Nov 8, 2005
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.